Before the opening bell, International Stem Cell Corporation
(OTCQB: ISCO) announced its operating results for the first quarter of 2016.
The company’s consolidated revenue for the three months ended March 31 was $1.6
million, which remained unchanged from the comparable period of 2015. ISCO
continued to generate revenue through its two wholly-owned subsidiaries,
Lifeline Skin Care and Lifeline Cell Technology, with both remaining
profitable. Profit margin for the two subsidiaries was $1.24 million, or 77 percent,
for the three month period, up from $1.20 million, or 74 percent, in the
previous year.
“I’m happy to report that while revenues remained flat,
profit margin improved,” Andrey Semechkin, Ph.D., chief executive officer and
co-chairman of ISCO, stated in this morning’s news release. “In addition our
therapeutic development programs are proceeding according to plan.”
In recent months, ISCO has continued to focus on the
clinical development of its groundbreaking human parthenogenetic stem
cell-derived neural stem cells (ISC-hpNSC®) for the treatment of moderate to
severe Parkinson’s disease. In December, the company receive authorization from
the Therapeutics Goods Administration of Australia to commence the first human
study of the cells, a phase I/IIa dose escalation trial. ISCO then entered into
a clinical service agreement with the Florey Institute of Neuroscience and
Mental Health, one of the world’s leading brain research centers, to conduct
the trial.
In March, the company took two significant steps in the
development of ISC-hpNSC®, including commencing enrollment for its impending
phase I trial and raising capital with which to fund the study through a
private placement. As part of this funding initiative, ISCO entered into
definitive agreements with two institutional healthcare investors and
management for the private placement of $6.3 million of the company’s
convertible preferred stock, as well as common stock purchase warrants for an
additional $25.7 million of ISCO’s common stock. Gross proceeds from this
placement included $2.5 million in cash and conversion of $3.8 million in debt,
which was owed to the company’s co-chairman and CEO.
“The recurring investment of these healthcare focused
institutional investors is in support of and attests to the potential of our
technology,” Semechkin added in a news release announcing the private
placement. “The capital raised will help to drive our Phase 1 study of
ISC-hpNSC® for the treatment of moderate to severe Parkinson’s disease. With
enrollment of patients already underway, we look forward to the end of this
year for preliminary safety and efficacy clinical data.”
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment